Interestingly, the short-term expression of the anti-PD-L1 antibody (which was undetectable at day five post-SFV-aPDL1 administration) was sufficient to induce potent and long-lasting antitumor responses, promoting tumor-specific CD8+ T-cell infiltration in both tumor models. This evidence concerns the gene CD8A and neoplasm.